Introduction
============

In vitro and in vivo experiments have demonstrated a potent yet opposite effect of IL-2 on both regulatory T cells (T~REG~) and IL-17+CD45RA-CD4+ T cells (Th17). T~REG~ cells have been implicated as an important immunoregulator enhancing tumor growth whereas Th17 cells may mediate tumor destruction. This study compares the effect of high-dose IL-2 (HDIL-2) on both the TREG and Th17 compartments in responders and non-responders.

Methods
=======

Peripheral blood was collected at baseline and at 24, 48, 72, and 96 hours post-treatment from 6 patients undergoing HDIL-2 therapy under an IRB approved protocol. No patients enrolled received anti-PD-1 or anti-CTLA4 therapies. PBMCs were isolated and underwent intracellular cytokine and extracellular receptor staining for flow cytometry. Statistical analysis was performed using paired student\'s t tests via Prism 6.0e software.

Results
=======

5 of 6 patients clinically progressed on HDIL-2 therapy (non-responders, NR), and these patients demonstrated an increase in the frequency of CD25+FoxP3+CD4+ T cells (T~REG~) on day 4 of treatment (4% +/- 1% on day 0 to 14% +/- 6% on day 4, p value = 0.06). A single patient responded to HDIL-2 therapy (complete responder, CR) and demonstrated a decrease in the frequency of T~REG~ cells on day 4 of treatment (9% on day 0 to 7% on day 4). HDIL-2 increased the frequency of IL-17+CD45RA-CD4+ T cells (Th17) on day 4 of therapy in all patients analyzed (0.7% +/- 0.4% on day 0 versus 2% +/- 1% on day 4, p value=0.04; Figure [1](#F1){ref-type="fig"}). Absolute numbers of Th17 cells also demonstrated a statistically significant increase on day 4 of therapy (5 +/- 1 cell/µL on day 0 versus 38 +/- 24 cells/µL on day 4, p value=0.04, Figure [2](#F2){ref-type="fig"}). Subsequent analyses demonstrated a negative Th17:T~REG~ ratio on day 4 of HDIL-2 treatment in all non-responders. Importantly, the complete responder demonstrated a positive Th17:T~REG~ ratio on day 4 of treatment (Figure [3](#F3){ref-type="fig"}). The observed difference in cytokine production appeared to be specific to IL-17 as there was no statistically significant change in frequency or total numbers of IFN-g+ or IL-2+CD4+ and CD8+ T cells.
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Conclusion
==========

Our results suggest a distinct immunophenotype indicative of response to HDIL-2. Analysis of peripheral T~REG~ and Th17 cell frequencies early in the course of HDIL-2 therapy may help identify those patients who would benefit from subsequent cycles.
